• Je něco špatně v tomto záznamu ?

Possible Therapeutic Potential of Disulfiram for Multiple Myeloma

D. Weiser Drozdkova, K. Smesny Trtkova

. 2021 ; 28 (3) : 2087-2096. [pub] 20210603

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, práce podpořená grantem, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc21025611

Multiple myeloma (MM) is a malignant disease of the plasma cells representing approximately 10% of all hemato-oncological diseases. Detection of the disease is most probable at around 65 years of age, and the average survival of patients is estimated to be 5-10 years, specifically due to frequent relapses and resistance to the therapy used. Thus, the search for new therapeutic approaches is becoming a big challenge. Disulfiram (DSF), a substance primarily known as a medication against alcoholism, has often been mentioned in recent years in relation to cancer treatment for its secondary anti-cancer effects. Recent studies performed on myeloma cell lines confirm high inhibition of the cell growth activity if a complex of disulfiram and copper is used. Its significant potential is now being seen in the cure of haematological malignities.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21025611
003      
CZ-PrNML
005      
20211026133645.0
007      
ta
008      
211013s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/curroncol28030193 $2 doi
035    __
$a (PubMed)34205025
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Weiser Drozdkova, Denisa $u Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University, 77900 Olomouc, Czech Republic
245    10
$a Possible Therapeutic Potential of Disulfiram for Multiple Myeloma / $c D. Weiser Drozdkova, K. Smesny Trtkova
520    9_
$a Multiple myeloma (MM) is a malignant disease of the plasma cells representing approximately 10% of all hemato-oncological diseases. Detection of the disease is most probable at around 65 years of age, and the average survival of patients is estimated to be 5-10 years, specifically due to frequent relapses and resistance to the therapy used. Thus, the search for new therapeutic approaches is becoming a big challenge. Disulfiram (DSF), a substance primarily known as a medication against alcoholism, has often been mentioned in recent years in relation to cancer treatment for its secondary anti-cancer effects. Recent studies performed on myeloma cell lines confirm high inhibition of the cell growth activity if a complex of disulfiram and copper is used. Its significant potential is now being seen in the cure of haematological malignities.
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a měď $7 D003300
650    12
$a disulfiram $x terapeutické užití $7 D004221
650    _2
$a lidé $7 D006801
650    12
$a mnohočetný myelom $x farmakoterapie $7 D009101
650    _2
$a lokální recidiva nádoru $7 D009364
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Smesny Trtkova, Katerina $u Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University, 77900 Olomouc, Czech Republic $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, 77900 Olomouc, Czech Republic
773    0_
$w MED00165427 $t Current oncology (Toronto, Ont.) $x 1718-7729 $g Roč. 28, č. 3 (2021), s. 2087-2096
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34205025 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026133651 $b ABA008
999    __
$a ok $b bmc $g 1714591 $s 1146118
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 28 $c 3 $d 2087-2096 $e 20210603 $i 1718-7729 $m Current oncology $n Curr. oncol. $x MED00165427
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Možnosti archivace